Funding ambitious research in longevity and neuroscience
Grants
We’ve funded research, initiatives, and programs making breakthroughs in aging and neuroscience
Our mission is to engage skilled researchers and support ambitious ideas in the longevity and neuroscience fields. In the past few years, we have donated and committed over $50M to research spanning neuroAI, brain aging, centenarian genetics, and next-gen neurotechnologies.
Featured
Read more about our projects, roadmaps, and grants
-
![]()
NeuroAI for AI Safety Whitepaper Launches
This whitepaper outlines how NeuroAI can be a differential path to building safer AI systems, led by Patrick Mineault with Joanne Peng and Niccolo Zanichelli. We can drastically accelerate this path in <7 years with scalable approaches anchored in data. The intermediate steps also enable virtual neuroscience and shorten the translational timelines for new neurotechnology.
-
![]()
The Enigma Project Launches
The Enigma Project at Stanford in partnership with IMEC, launches out of stealth to decode the brain, led by Andreas Tolias, Tirin Moore, Sophia Sanborn, and Barun Dutta.
-
![]()
Xin Jin (Scripps) Publishes New Paper
Partially funded by Amaranth, Xin Jin (Scripps) publishes a paper titled “Massively parallel in vivo Perturb-seq reveals cell-type-specific transcriptional networks in cortical development”, a leap from existing capabilities.
-
![]()
Forest Neurotech Announces New Funding
Convergent Research announces $18M in funding for Forest Neurotech with support from Eric Schmidt, Griffin Catalyst, the Riley & Susan Bechtel Foundation, and James Fickel.
-
![]()
Aging is No Blessing
Policy and ethics lead Raiany Romanni writes for Palladium Magazine. “By our first full decade of life, we’d never think to ask: why did lobsters grow wise and strong, while we grew wise and frail?”
-
![]()
Bottlenecks of Aging
A comprehensive report from our scientific advisory board and team consisting of bottlenecks of the field, and specific actionable projects that can unlock progress.
-
![]()
XPrize Launch
Our policy and ethics lead, Raiany Romanni, writes about the recent $101M XPrize launch to extend human healthspan.
-
![]()
Brain Aging White Paper
Led by Amaranth internal lead Rohan Krajeski, this paper explores understudied approaches to brain aging — endogenous neurogenesis, exogenous replacement of cells and tissues, extracellular matrix repair, and learning from non-model organisms.
-
![]()
Spatial Multiplexing Technology
Partially funded by Amaranth, the Boyden lab at MIT has developed a way to simultaneously image up to five different molecules within a cell, by targeting glowing reporters to distinct locations inside the cell.
-
![]()
Summer Course on Aging
The Biology of Aging course teaches newcomer scientists the fundamentals of geroscience. It is led by Jennifer Garrison and William Mair in partnership with the Marine Biological Laboratory.
-
![]()
Time Initiative
In partnership with the American Federation of Aging Research and led by Amaranth’s internal lead, Courtney Hudson-Paz, the Time Initiative’s goal is to accelerate young talent in aging biology through a fellowship program. Meet the 2023 fellows here!
-
![]()
Amaranth Prize
The Amaranth Prize powered by Research Portfolio gives no-strings-attached funding to the best research in longevity. It rewards research retrospectively. See the winning papers for the 2023 prize on protein aging here.
-
![]()
Impetus Grants
Impetus Grants provide fast grants up to $500k within 3 weeks for scientists to work on aging biology. It is led by Amaranth board member Martin Borsch Jensen and Lada Nuzhna.
Our Team
We are a group of scientists and entrepreneurs accelerating transformative science
Core Team
-
James is an early Ethereum investor and founded Amaranth to accelerate research in longevity.
He assembled Amaranth’s scientific advisory board, a group of young leaders in longevity biotech, to source and evaluate ambitious research covering the aggregome, centenarian genetics, cryopreservation, germline rejuvenation and brain aging. He has backed the Norn Group, Impetus Grants, the SuperAgers Family Initiative, the Time Initiative Undergraduate Fellows Program, the MBL Aging Course, as well as labs from Harvard, MIT, and Stanford.
-
Joanne is currently at Princeton and the Boyden Lab at MIT, where she works on tools for brain aging including spatial proteomics and whole brain modeling. Previously, she was a Thiel Fellow, where she worked on mitochondrial dynamics at the Biomedical Institute at MaRS, COVID testing at Curative, and cancer research at the Buck Institute.
Joanne has been supported by the Thiel Fellowship, Interact Fellowship, Day One Project, the Institute for Progress, the Davis UWC Foundation, and VitaDAO.
-
Patrick is a neuroscience and artificial intelligence researcher. He spends his time at Amaranth creating a path toward safe AI by learning from the brain.
Patrick obtained a PhD in neuroscience from McGill University. He was a data scientist and software engineer at Google, a brain-computer inferface engineer at Meta, a senior machine learning scientist at Mila, and was a co-founder of Neuromatch.
-
Josh is a postdoctoral scholar in the Andreasson Lab at Stanford where he studies how immune cells outside of the brain influence Alzheimer’s disease progression. He has a PhD from the University of California, Irvine with Dr. Kim Green, where he explored the dynamics of extracellular matrix remodeling by microglia in healthy and pathological brain aging.
Josh has over a decade of research experience and has published extensively about the role of neuroinflammation in models of aging and neurodegenerative disease.
-
Jarod is an interdisciplinary scientist with an entrepreneurial streak and contrarian instincts. He spends his time at Amaranth thinking about ways to accelerate the science of healthy life extension towards a positive sci-fi future where we are all healthier, happier, and more vital than ever before.
Jarod holds a Ph.D. in genetics from Stanford University, where he worked with professors Tony Wyss-Coray and Stephen Montgomery to pioneer new methods to measure aging with proteomics. He then went on to a postdoctoral fellowship at EMBL and Stanford in computer vision with professors Anna Kreshuk and Lars Steinmetz, where he developed high-throughput technologies which merged CRISPR and AI to perturb single cells at scale. He also has extensive research experience in medicinal chemistry, materials science, and synthetic biology at top institutions around the world, and aspires to be a polymath across all domains of science and technology.
-
Raiany spends most of her time thinking about how converging technologies will transform governments and human nature in the coming decades.
She's particularly interested in why secular humans like to narrate aging as a net-positive, teleological phenomenon — and in the negative effects of this narrative on economies and people. Her work has appeared in outlets like The Washington Post, The Boston Globe, Forbes, and ABC. Raiany is currently working on a book aimed at shifting the ethics, policy and philosophy of life extension.
-
Niccolò is an artificial intelligence researcher and computer science student, working at the intersection between machine learning and biology.
At Amaranth, Niccolò works on the neuroAI program.
Advisory Board
-
Martin is the CSO of Gordian Biotechnology, which develops pooled in vivo therapeutic screening to find effective therapies against underserved diseases of aging. He is also the president of the Norn Group, a non-profit supporting projects to accelerate aging research, including Impetus Grants and the Longevity Apprenticeship.
Prior to his current role, Martin was a K99 Fellow in the Jasper Lab at the Buck Institute, where he conducted research on a range of cellular mechanisms involved in aging, such as mitochondrial function, NAD metabolism, DNA damage signaling, and stress responses. Martin received his PhD in Biogerontology from the National Institute of Aging and University of Copenhagen in Vilhelm Bohr’s lab.
-
Aaron is the CEO of Revel Pharmaceuticals, which develops repair based therapies for aging and disease. He co-founded Revel in 2019 to focus on clearing the excess accumulation of toxic proteins and metabolites implicated in aging.
Before Revel, Aaron worked at Google X and consulted for various biotech companies. Aaron has over eight years of experience in Revel’s platform technologies of enzyme discovery and engineering, and received his PhD in Bioengineering from Stanford University advised by Dr. Christina Smolke. Aaron holds a bachelors of mathematics from the University of Rochester.
-
Alex joined Laura Deming to build the next evolution of the Longevity Fund, called age1, as General Partner, to invest in and catalyze ambitious founder-led longevity biotech companies.
Previously he was Chief of Staff at the Amaranth Foundation where he built out the longevity focus of the family office. Alex completed his PhD in Genetics at Stanford University in Tom Rando's lab studying the biology of aging after having worked in Boston in management consulting at Putnam Associates, a boutique life sciences consulting firm.
-
Laura is a cofounder and Venture Partner of age1 and was previously the founder and General Partner of The Longevity Fund. Her work focuses on human life extension and using biological research to reduce the effects of aging.
Laura took graduate coursework at UCSF before going to MIT to study physics, which she eventually dropped out of to become a Thiel Fellow. She’s worked in the Kenyon, Guarente, Weiss and Firestein labs on a number of topics, including aging and synthetic biology. Laura founded the Longevity Fund in 2011, the first VC firm dedicated to funding longevity companies, which raised $37M and has had 5 IPOs with portfolio companies raising over a billion dollars in follow-on funding. The Longevity Fund has backed leading longevity biotechs including Loyal, Gordian, Fauna Biotech, Spring Discovery, Arda Therapeutics, and Rubedo Life Sciences.
-
Kristen is the co-founder and CEO of BioAge, a clinical-stage biotechnology company developing a pipeline of therapies to extend healthy lifespan by targeting the molecular causes of aging.
Kristen’s scientific background is in aging biology and bioinformatics. She received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University, where she was a fellow of the Ellison Medical Foundation & American Federation for Aging Research. She is an advisor to multiple biotechnology companies. In 2023, Fierce Pharma named Kristen as one of the most influential people in biopharma.
-
Adam is the CEO of Convergent Research, launching Focused Research Organizations (FROs), such as E11 bio and Cultivarium. He also serves on the boards of several non-profits pursuing new methods of funding and organizing scientific research including Norn Group, New Science, and Amaranth.
Previously, he was a Schmidt Futures Innovation Fellow, a consultant for the Astera Institute, a Fellow with the Federation of American Scientists (FAS), a research scientist at Google DeepMind, Chief Strategy Officer of the brain-computer interface company Kernel, a research scientist at MIT, a PhD student in biophysics with George Church and colleagues at Harvard, and a theoretical physics student at Yale. He also previously helped to start companies like BioBright, and advised foundations such as the Open Philanthropy Project. His work has been recognized with a Technology Review 35 Innovators Under 35 Award (2018), a Fannie and John Hertz Foundation Fellowship (2010) and a Goldwater Scholarship (2008).
Engage
Ways to connect with us
APPLY
For rigorously reasoned, moonshot projects in every form: academic, focused research, startup, and independent contributors.
Newsletter
Subscribe to our Substack for the latest news, project launches, whitepapers, and requests for proposals.